-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports of Yimaike ★The opening of the era of engineered iPSC immune cell therapyNew observations of Yimai ★Allogene universal BCMA CAR-T cells have been designated by the US FDA Fast TrackYimai Meng broke the news.
Click on the picture and register now July 3, 2021 /MedClub News/--On July 1, 2021, Precision BioSciences, a clinical-stage biotechnology company, announced today that the company's drug PBCAR19B phase 1 clinical trial has completed its first patient administration
.
PBCAR19B is the company's allogeneic "stealthcell candidate" targeting CD19 for the treatment of relapsed/refractory (R/R) non-Hodgkin's lymphoma (NHL) Patient
.
The drug has an immune evasion effect, can "invisible" in front of T cells and NK cells, reduce the rejection of T cells and NK cells, and improve the expansion and persistence of allogeneic CAR-T cells after infusion
.
Using its proprietary ARCUS® genome editing platform, PBCAR19B transfers the CAR gene and a short hairpin RNA (shRNA) into T cells through a stealth vector
.
The shRNA can inhibit the expression of β2 microglobulin (B2M), which is a component of the major histocompatibility complex (MHC I) on the cell surface
.
Reducing or knocking out the expression of MHC I on the surface of allogeneic CAR-T cells can reduce the killing effect of cytotoxic T cells on CAR-T cells
.
However, NK cells can be stimulated due to the decreased expression of MHC molecules on the cell surface, so the PBCAR19B vector also carries an HLA-E gene to reduce the rejection of CAR-T cells by NK cells
.
Alan List, MD, Chief Medical Officer of Precision BioSciences, said: “We believe that ARCUS’s technology for editing stealth cells has the potential to improve the persistence of allogeneic CAR-T cells on the premise of safety without the need for prolonged immunosuppression.
This may ultimately Bring a deeper and longer-lasting response to patients
.
"The phase 1 clinical trial (NCT04649112) is a non-random, open-label, single-dose, dose-escalation and dose-expansion study to evaluate the safety and clinical activity of PBCAR19B
.
The FDA passed the IND application for this trial in January 2021
.
Recommended reading: Allogeneic "invisible" CD19 CAR-T cells that will not be found by T cells and NK cellsYi Mai Meng revealed the advantages and disadvantages of allogeneic CAR-T allogeneic, also known as "spot" (Off-the-shelf) is the collection of T cells from healthy donors or T cells derived from iPSCs, which are engineered to express CAR to identify and destroy cancer cells
.
Universal CAR-T therapy helps improve patient accessibility, but this therapy also faces many challenges.
The first is the immune response from allogeneic transplantation
.
About ARCUS®ARCUS is the company's unique, highly specific and versatile genome editing platform, which is designed with treatment safety, delivery and control in mind
.
In November 2020, Eli Lilly and Precision Corporation reached a cooperation to use the ARCUS gene editing platform to develop potential therapies for genetic diseases, and announced its official entry into the field of gene editing therapy
.
Recommended reading: Target DMD! Eli Lilly’s US$135 million ticket to enter the field of gene editingYimai Meng broke the news ▲ Precision’s ARCUS platform process (source: official website) The core of the ARCUS platform is ARCUS nuclease, which has naturally occurring gene editing properties and Provide safer and more specific gene editing
.
For more details, scan the QR code to read the complete reference materials: 1.
https:// -t-clinical-trial-of-pbcar19b-immune-evading-stealth-cell-for-relapsed-refractory-non-hodgkin-lymphoma/YiMike has always been committed to the cutting-edge technology, industry trends, industry insights and other originals of bio-innovative drugs According to news reports, all-media high-end matrix users reached 160,000+, of which industrial users accounted for more than 50%, scientific research and clinical users accounted for about 30%, and investment institutions accounted for more than 5%
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
Click on the picture and register now July 3, 2021 /MedClub News/--On July 1, 2021, Precision BioSciences, a clinical-stage biotechnology company, announced today that the company's drug PBCAR19B phase 1 clinical trial has completed its first patient administration
.
PBCAR19B is the company's allogeneic "stealthcell candidate" targeting CD19 for the treatment of relapsed/refractory (R/R) non-Hodgkin's lymphoma (NHL) Patient
.
The drug has an immune evasion effect, can "invisible" in front of T cells and NK cells, reduce the rejection of T cells and NK cells, and improve the expansion and persistence of allogeneic CAR-T cells after infusion
.
Using its proprietary ARCUS® genome editing platform, PBCAR19B transfers the CAR gene and a short hairpin RNA (shRNA) into T cells through a stealth vector
.
The shRNA can inhibit the expression of β2 microglobulin (B2M), which is a component of the major histocompatibility complex (MHC I) on the cell surface
.
Reducing or knocking out the expression of MHC I on the surface of allogeneic CAR-T cells can reduce the killing effect of cytotoxic T cells on CAR-T cells
.
However, NK cells can be stimulated due to the decreased expression of MHC molecules on the cell surface, so the PBCAR19B vector also carries an HLA-E gene to reduce the rejection of CAR-T cells by NK cells
.
Alan List, MD, Chief Medical Officer of Precision BioSciences, said: “We believe that ARCUS’s technology for editing stealth cells has the potential to improve the persistence of allogeneic CAR-T cells on the premise of safety without the need for prolonged immunosuppression.
This may ultimately Bring a deeper and longer-lasting response to patients
.
"The phase 1 clinical trial (NCT04649112) is a non-random, open-label, single-dose, dose-escalation and dose-expansion study to evaluate the safety and clinical activity of PBCAR19B
.
The FDA passed the IND application for this trial in January 2021
.
Recommended reading: Allogeneic "invisible" CD19 CAR-T cells that will not be found by T cells and NK cellsYi Mai Meng revealed the advantages and disadvantages of allogeneic CAR-T allogeneic, also known as "spot" (Off-the-shelf) is the collection of T cells from healthy donors or T cells derived from iPSCs, which are engineered to express CAR to identify and destroy cancer cells
.
Universal CAR-T therapy helps improve patient accessibility, but this therapy also faces many challenges.
The first is the immune response from allogeneic transplantation
.
About ARCUS®ARCUS is the company's unique, highly specific and versatile genome editing platform, which is designed with treatment safety, delivery and control in mind
.
In November 2020, Eli Lilly and Precision Corporation reached a cooperation to use the ARCUS gene editing platform to develop potential therapies for genetic diseases, and announced its official entry into the field of gene editing therapy
.
Recommended reading: Target DMD! Eli Lilly’s US$135 million ticket to enter the field of gene editingYimai Meng broke the news ▲ Precision’s ARCUS platform process (source: official website) The core of the ARCUS platform is ARCUS nuclease, which has naturally occurring gene editing properties and Provide safer and more specific gene editing
.
For more details, scan the QR code to read the complete reference materials: 1.
https:// -t-clinical-trial-of-pbcar19b-immune-evading-stealth-cell-for-relapsed-refractory-non-hodgkin-lymphoma/YiMike has always been committed to the cutting-edge technology, industry trends, industry insights and other originals of bio-innovative drugs According to news reports, all-media high-end matrix users reached 160,000+, of which industrial users accounted for more than 50%, scientific research and clinical users accounted for about 30%, and investment institutions accounted for more than 5%
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
